Next Article in Journal
Studies on Anti-Cancer Agents from Natural Resources with Special Reference to Cannabis sativa and Datura metel L.
Previous Article in Journal
Computational Investigations of Arylnaphthalene Lignan Lactones as Anticancer Agents
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Proceeding Paper

In Silico Pharmacological Prediction of Capitavine, Buchenavianine and Related Flavonoid Alkaloids †

by
Renata Gašparová
* and
Natália Kabaňová
Department of Chemistry, Institute of Chemistry and Environmental science, Faculty of Natural Sciences, University of Ss. Cyril and Methodius in Trnava, Nám. J. Herdu 2, SK-917 01 Trnava, Slovakia
*
Author to whom correspondence should be addressed.
Presented at the 28th International Electronic Conference on Synthetic Organic Chemistry (ECSOC-28), 15–30 November 2024; Available online: https://sciforum.net/event/ecsoc-28.
Chem. Proc. 2024, 16(1), 55; https://doi.org/10.3390/ecsoc-28-20222
Published: 14 November 2024

Abstract

:
Flavonoid alkaloids represent an interesting subgroup of the alkaloid family. Several plants containing flavonoid alkaloids are used in folk medicine for the treatment of various diseases. The interesting biological properties of flavonoid alkaloids make them attractive candidates for lead compounds in drug discovery. Capitavine, or 5,7-dihydroxy-6-(1-methylpiperidin-2-yl)flavone, and related compounds, belong to piperidine–flavonoid alkaloids, possessing a piperidine ring connected to the C6-position of flavonoid skeleton, while buchenavianine is C8 piperidine-bonded analog. Capitavine derivatives were isolated mainly from Buchenavia capitata, while buchenavianine derivatives are present mainly in B. macrophylla. It was found that the chloroform extract of the leaves of B. capitata showed anti-HIV activity. The biological activity of capitavine and buchenavianine derivatives needs to be investigated in terms of their pharmacokinetic properties and toxicity, which are important factors in finding potential drug candidates. The present in silico study using SwissADME, Osiris, and Molinspiration software shows that studied capitavine-derived flavonoid alkaloids exhibit considerable bioactivity for the GPCR ligand (0.12 to 0.20), as enzyme inhibitors (0.17 to 0.22) and as nuclear receptor ligands (0.07 to 0.28). All compounds exhibit good gastrointestinal absorption and low risks of being irritants, tumorigenic, or having a reproductive effect. The risk of mutagenicity was calculated for two compounds related to buchenavianine, and at this point the role of 5-methoxy group appears to be crucial for the low risk of mutagenicity.

1. Introduction

Capitavine 1 (Figure 1) is a flavonoid alkaloid from the seeds of Buchenavia capitata Eichler, Combretaceae [1,2]. Two other capitavine derivatives, 4′-hydroxycapitavine 3 and 2,3-dihydro-4′-hydroxycapitavine 4, were also isolated from the same plant, while N-demethylcapitavine 2 and 2,3-dihydrocapitavine 5, respectively, were found only in the fruits of Buchenavia macrophylla Eichler [3]. Buchenavianine 6 (Figure 1) is the major alkaloid from the leaves of B. macrophylla. Similar alkaloids, namely O-demethylbuchenavianine 7, N-demethylbuchenavianine 8, and N,O-bisdemethylbuchenavianine 9 have been isolated from the fruits of B. macrophylla [3]. Capivatine-related compounds belong to flavonoid alkaloids, possessing a piperidine ring connected to the C6-position of the flavonoid skeleton. On the other hand, structurally similar buchenavianine and its derivatives are C8 piperidine-bonded analogs. Biological activity evaluation of the chloroform extract of the leaves of B. capitata was accomplished by Beutler et al. [4]. The results show a potential anti-HIV activity of B. capitata constituents, and indicate that O-demethylbuchenavianine 7 is the most active component. In general, natural products and their structural analogs represent a rich source of pharmacologically important substances. However, drug discovery is a challenge due to the isolation, structure elucidation, and biological activity screening of a large number of structures. Therefore, various in silico tools have been created. SwissADME, Osiris, and Molinspiration (SOM) analysis enables access to the pharmacokinetic profile of the synthesized molecules and their toxicity [5,6].

2. Material and Methods

Molinspiration Cheminformatics [7] was used for the calculation of molecular properties (logP, TPSA, number of H-bond donors and acceptors) and prediction of the bioactivity score for the most important drug targets (GPCR ligands, ion channel modulators, kinase inhibitors, nuclear receptor ligands, protease, or enzyme inhibitors). SwissADME software [8] was used for the pharmacokinetic parameter calculations, mainly gastrointestinal absorption, blood–brain barrier permeation, the assessment of whether a compound is a substrate or non-substrate of P-gp, the interactions of the molecule with the cytochrome P450 or skin permeability (Log Kp). The drug-likeness score, using five different methods (Lipinski, Ghose, Veber, Egan, and Muegge), the bioavailability score, PAINS and Brenk structural alerts, lead-likeness and synthetic accessibility were calculated. Osiris Property Explorer [9] was used to calculate the toxicity risk (mutagenicity, tumorigenicity, irritating effects, and reproductive effects) of flavonoid alkaloids 19, exprimed in semaphore colors.

3. Results and Discussion

3.1. Molinspiration

Lipinski’s rule of five [10] is a computational method for developing tools to design orally active compounds and selecting drug molecules for further development. According to Lipinski’s rule, only a molecule with MW ≤ 500, LogP ≤ 5, number of H-donors (OH, NH) ≤ 5, and number of H-acceptors (O, N) ≤ 10 could be a good drug candidate. Moreover, as Verber et al. [11] observed, compounds with TPSA ≤ 140 Å and number of the rotatable bonds ≤ 10 have good oral bioavailability. All flavonoid alkaloids 1-9 are in accordance with both Lipinski’s and Verber’s rules (Table 1).
Results of Molinspiration bioactivity score prediction suggest that studied flavonoid alkaloids should exhibit considerable bioactivity towards GPCR ligands, nuclear receptor ligands, or as kinase and other enzyme inhibitors, which are exprimed by the positive bioactivity score values (Table 1). Calculated GPCR, NRL, and EI scores of C2–C3 hydrogenated capitavines 4 and 5 reached high values (0.20–0.28).

3.2. SwissADME

SwissADME predictions given in Table 2 show that all studied flavonoid alkaloids 19 exhibit high gastrointestinal absorption (GIA). Blood–brain barrier (BBB) permeation is predicted for five compounds (1, 4, 68), and compounds 2, 3, 5 and 9 are unable to cross the BBB.
SwissADME enables prediction simultaneously of two key ADME parameters—the passive gastrointestinal absorption (GIA) and blood–brain barrier (BBB) permeation via the “Boiled egg” graphical model, which exprimes dependance of WLOGP [12] and TPSA (for lipophilicity and apparent polarity) [13]. As is shown in Figure 2, four studied compounds (1, 4, 6, 8) are placed in the “yolk” area, representing physicochemical space for highly probable BBB permeation. The white area represents the physicochemical space for highly probable GIA, with four compounds (2, 3, 5, 9). Studied compounds were predicted to be substrates of P-glycoprotein (P-gp), except N-demethylcapitavine 2. Inhibition of P-gp can increase drug absorption and bioavailability, and thus the therapeutic effects of the drug [14]. The results are shown in the boiled egg model, which allows the graphical output for P-gp substrates (blue dots) and P-gp non-substrates (red dots).
The study of potential drug interactions with cytochrome P450 isoenzymes is an important factor in drug design [15]. The SwissADME calculations have shown that all studied flavonoid alkaloids are inhibitors of at least one CYP. When compounds are predicted potential inhibitors of three or more CYPs (1, 2, 3, 8), they are predicted to be at risk of increased toxicity. All flavonoid alkaloids 19 are predicted not to be lead-like structures, mostly due to the MW being > 350 [16]. PAINS structural alert [17], associated with Mannich base (due to the structural unit N-C-C-C-OH) was calculated for all compounds.

3.3. Osiris

Calculations of toxicity risk prediction using Osiris software showed (Table 3) that all compounds 19 exhibit low risks in three categories—irritation, tumorigenicity, and reproductive effects. The highest risk of being mutagenic was calculated for two buchenavianine-related alkaloids, alkaloids 7 and 9.
Structures 7 and 9 possess a 5-hydroxy group, while buchenavianines 6 and 8 are 5-methoxy derivatives. It seems the role of 5-methoxy group may be crucial for a low risk of mutagenicity; however, more calculations should be carried out to confirm it. Drug score and drug-likeness values were also calculated (Table 3). The drug score indicates the potential of a compound to be a drug. Moderate drug score values were calculated for 7 and 9 (associated with high mutagenicity risk); other structures exhibit good drug score values.

4. Conclusions

Results of SOM analysis (SwissAdme/Osiris/Molinspiration) of capivatine and buchenavianine-derived flavonoid alkaloids show that studied compounds obey the Lipinski rule of five and exhibit high bioactivity scores for the following drug targets: GPCR and nuclear receptor ligands, kinase, and other enzyme inhibitors, which should indicate multiple mechanisms of the physiological action of the studied compounds. All compounds have good intestinal absorption; five of them are expected to permeate the BBB, but only one is expected not to be P-gp substrate. All compounds are considered non-toxic, except two 5-hydroxy-substituted buchenavianine derivatives with possible mutagenic effects.

Author Contributions

Conceptualization, methodology, software, validation, investigation, data curation, writing—original draft preparation, writing—review and editing, R.G.; formal analysis, resources, visualization, N.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data sharing is not applicable.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Khadem, S.; Marles, R.J. Chromone and Flavonoid Alkaloids: Occurrence and Bioactivity. Molecules 2012, 17, 191–206. [Google Scholar] [CrossRef] [PubMed]
  2. Ilkei, V.; Hazai, L.; Antus, S.; Bölcskei, H. Flavonoid Alkaloids: Isolation, Bioactivity, and Synthesis. Stud. Nat. Prod. Chem. 2018, 56, 247–285. [Google Scholar] [CrossRef]
  3. Ahond, A.; Fournet, A.; Moretti, C.; Philogene, E.; Poupat, C.; Thoison, O.; Potier, P. Premiers alcaloïdes vrais isolés de Combretacées: Buchenavia macrophylla Eichl. et Buchenavia capitata Eichl. Bull. Soc. Chim. Fr. Partie I 1984, 1–2, 41–45. [Google Scholar]
  4. Beutler, J.A.; Cardellina II, J.H.; McMahon, J.B.; Boyd, M.R.; Cragg, G.M. Anti-HIV and Cytotoxic Alkaloids from Buchenavia capitata. J. Nat. Prod. 1992, 55, 207–213. [Google Scholar] [CrossRef]
  5. Maliar, T.; Maliarová, M.; Purdešová, A.; Jankech, T.; Gerhardtová, I.; Beňovič, P.; Dvořáček, V.; Jágr, M.; Viskupičová, J. The Adapted POM Analysis of Avenanthramides in Silico. Pharmaceuticals 2023, 16, 717. [Google Scholar] [CrossRef] [PubMed]
  6. Apan, A.; Casoni, D.; Leonte, D.; Pop, C.; Iaru, I.; Mogosan, C.; Zaharia, V. Heterocycles 52: The Drug-Likeness Analysis of Anti-Inflammatory Thiazolo[3,2-b][1,2,4]triazole and Imidazo[2,1-b][1,3,4]thiadiazole Derivatives. Pharmaceuticals 2024, 17, 295. [Google Scholar] [CrossRef]
  7. Molinspiration Chemoinformatics Software. Available online: https://www.molinspiration.com/ (accessed on 1 June 2024).
  8. SwissADME Software. Available online: http://www.swissadme.ch/ (accessed on 10 June 2024).
  9. OSIRIS Property Explorer; Actelion Pharmaceuticals Ltd.: Allschwil, Switzerland, 2010; Available online: http://www.organic-chemistry.org/prog/peo/ (accessed on 5 June 2024).
  10. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23, 3–25. [Google Scholar] [CrossRef]
  11. Veber, D.F.; Johnson, S.R.; Cheng, H.Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem. 2002, 45, 2615–2623. [Google Scholar] [CrossRef] [PubMed]
  12. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 42717. [Google Scholar] [CrossRef] [PubMed]
  13. Daina, A.; Zoete, V. A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem 2016, 11, 1117–1121. [Google Scholar] [CrossRef] [PubMed]
  14. Nguyen, T.T.; Duong, V.A.; Maeng, H.J. Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability. Pharmaceutics 2021, 13, 1103. [Google Scholar] [CrossRef]
  15. Šestić, T.L.; Ajduković, J.J.; Marinović, M.A.; Petri, E.T.; Savić, M.P. In silico ADMET analysis of the A-, B- and D-modified androstane derivatives with potential anticancer effects. Steroids 2023, 189, 109147. [Google Scholar] [CrossRef] [PubMed]
  16. Teague, S.J.; Davis, A.M.; Leeson, P.D.; Oprea, T. The Design of Leadlike Combinatorial Libraries. Angew. Chem. Int. Ed. 1999, 38, 3743–3748. [Google Scholar] [CrossRef]
  17. Baell, J.B.; Holloway, G.A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 2010, 53, 2719–2740. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Capivatine 1, buchenavianine 6, and related flavoalkaloids.
Figure 1. Capivatine 1, buchenavianine 6, and related flavoalkaloids.
Chemproc 16 00055 g001
Figure 2. Prediction of passive diffusion of 19 through GIA and BBB in a “boiled egg” model (yolk—BBB permeation; white—GIA; blue dots—P-gp substrate; red dot—P-gp non-substrate). (Note: Dots of 4 and 7 are overlapped).
Figure 2. Prediction of passive diffusion of 19 through GIA and BBB in a “boiled egg” model (yolk—BBB permeation; white—GIA; blue dots—P-gp substrate; red dot—P-gp non-substrate). (Note: Dots of 4 and 7 are overlapped).
Chemproc 16 00055 g002
Table 1. Physiochemical properties and bioactivity scores of 19 calculated using Molinspiration software.
Table 1. Physiochemical properties and bioactivity scores of 19 calculated using Molinspiration software.
No.logPTPSAMWnA/nDrotGPCRICMKINRLPIEI
14.2373.91351.405/220.120.020.060.07−0.050.17
23.0982.69337.385/320.09−0.010.060.12−0.040.21
33.7594.13367.406/220.130.030.070.12−0.050.18
43.6870.00353.425/220.20−0.10−0.270.230.070.20
53.2090.23369.426/320.20−0.09−0.240.280.070.20
64.5162.91365.435/130.15−0.100.120.06−0.100.11
74.2373.91351.405/120.18−0.050.140.12−0.050.18
83.3671.70351.405/230.12−0.140.120.11−0.100.14
93.0982.69337.385/320.16−0.080.150.17−0.040.22
LogP—Octanol–water partition coefficient; TPSA—topological polar surface area; MW—molecular weight; nA—number of hydrogen bond acceptors (O, N); nD—number of hydrogen bond donors (OH, NH); rot—number of rotatable bonds; GPCR—GPCR ligand; ICM—ion channel modulator; KI—kinase inhibitor; NRL—nuclear receptor ligand; PI—protease inhibitor; EI—enzyme inhibitor.
Table 2. The SwissADME calculations of 19.
Table 2. The SwissADME calculations of 19.
NoGIABBBP-gpSCYPLipinskiGhoseVeberEgan MueggePAINSBrenkLLSALogKpBA
1HYYY,Y,Y,Y,YYYYYY10N3.69−5.790.55
2HNYY,Y,Y,Y,YYYYYY10N3.58−5.680.55
3HNNN,N,Y,Y,YYYYYY10N3.72−5.890.55
4HYYN,N,N,Y,YYYYYY10N3.73−6.000.55
5HNYN,N,N,Y,YYYYYY10N3.81−6.250.55
6HYYN,N,N,Y,YYYYYY10N3.95−6.240.55
7HYYN,N,N,Y,YYYYYY10N3.83−6.000.55
8HYYN,Y,N,Y,YYYYYY10N3.84−6.490.55
9HNYN,N,N,Y,NYYYYY10N3.73−6.250.55
Y—yes; N—no; GIA—gastrointestinal absorption; BBB—blood–brain barrier permeation; P-gpS—P-glycoprotein substrate; CYP—cytochrome P450 (1A2, 2C19, 2C9, 2D6, 3A4) inhibitors; PAINS—pan assay interference structures; Brenk—structural alert by Brenk; LL—lead-likeness; SA—synthetic accessibility; LogKp—skin permeation (cm/s); BA—bioavailability score.
Table 3. OSIRIS toxicity risk, druglikeness and drug score calculations of 19.
Table 3. OSIRIS toxicity risk, druglikeness and drug score calculations of 19.
NoMUTTUMIRR REPDLDS
1++++++++3.520.70
2++++++++0.520.63
3++++++++3.680.79
4++++++++4.120.79
5++++++++4.060.81
6++++++++3.570.71
7-++++++3.520.46
8++++++++0.610.59
9-++++++0.520.38
MUT—mutagenicity; TUM—tumorigenicity; IRR—irritant; RE—reproductive effect; DL—drug-likeness; DS—drug score. (++)—low toxicity risk; (-)—high toxicity risk.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Gašparová, R.; Kabaňová, N. In Silico Pharmacological Prediction of Capitavine, Buchenavianine and Related Flavonoid Alkaloids. Chem. Proc. 2024, 16, 55. https://doi.org/10.3390/ecsoc-28-20222

AMA Style

Gašparová R, Kabaňová N. In Silico Pharmacological Prediction of Capitavine, Buchenavianine and Related Flavonoid Alkaloids. Chemistry Proceedings. 2024; 16(1):55. https://doi.org/10.3390/ecsoc-28-20222

Chicago/Turabian Style

Gašparová, Renata, and Natália Kabaňová. 2024. "In Silico Pharmacological Prediction of Capitavine, Buchenavianine and Related Flavonoid Alkaloids" Chemistry Proceedings 16, no. 1: 55. https://doi.org/10.3390/ecsoc-28-20222

APA Style

Gašparová, R., & Kabaňová, N. (2024). In Silico Pharmacological Prediction of Capitavine, Buchenavianine and Related Flavonoid Alkaloids. Chemistry Proceedings, 16(1), 55. https://doi.org/10.3390/ecsoc-28-20222

Article Metrics

Back to TopTop